加载中
NYSEHealthcareMedical - Diagnostics & Research
最新数据
US$155.61
+US$1.43 · +0.93%
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
前收盘价
US$155.61
+US$1.43 · +0.93%
盘后
US$155.61
US$0.00 · 0.00%
10月12日 16:39 ET
盘中时间采用ET。市场数据可能有所延迟。
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
日内区间
当前US$155.61
52周区间
当前US$155.61
盘中时间采用ET。市场数据可能有所延迟。
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
日内区间
当前US$155.61
52周区间
当前US$155.61
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 28.56亿 USD | 27.55亿 USD | 27.51亿 USD | 33.12亿 USD | 38.28亿 USD |
| 销货成本 | 13.4亿 USD | 14.32亿 USD | 14.28亿 USD | 15.51亿 USD | 15.46亿 USD |
| 毛利 | 15.16亿 USD | 13.23亿 USD | 13.22亿 USD | 17.61亿 USD | 22.82亿 USD |
| 研究与开发 | 2.16亿 USD | 1.97亿 USD | 2.17亿 USD | 2.22亿 USD | 2亿 USD |
| 销售、一般及管理费用 | 9.45亿 USD | 7.15亿 USD | 7.06亿 USD | 7.58亿 USD | 7.42亿 USD |
| 营业费用 | 11.59亿 USD | 9.12亿 USD | 9.23亿 USD | 9.8亿 USD | 9.42亿 USD |
| 利息收入 | 3110.3万 USD | 7319万 USD | 7213.1万 USD | 358.9万 USD | 224.1万 USD |
| 利息支出 | 9218.5万 USD | 9627.8万 USD | 9881.3万 USD | 1.04亿 USD | 1.02亿 USD |
| 折旧和摊销 | 4.05亿 USD | 4.28亿 USD | 4.32亿 USD | 4.27亿 USD | 3.11亿 USD |
| 营业利润 | 3.57亿 USD | 4.11亿 USD | 3.99亿 USD | 7.81亿 USD | 13.4亿 USD |
| 净利润 | 2.42亿 USD | 2.96亿 USD | −1.18亿 USD | 5.69亿 USD | 9.43亿 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T332.18亿0.03%129.43万亿 JPY0.09%JP¥123,000+0.12%
Vanguard Morningstar Total Stock Market ETFVTI4.56亿0.02%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard S&P 500 ETFVOO3.81亿0.02%1.8万亿 USD0.03%US$715.13-0.06%
Vanguard Morningstar Small-Cap ETFVB3.3亿0.18%1853亿 USD0.03%US$288.16-0.46%
iShares Core S&P 500 ETFIVV2.29亿0.03%8964.4亿 USD0.03%US$781.44-0.07%
Vanguard Morningstar Small-Cap Value ETFVBR2.1亿0.31%682亿 USD0.05%US$234.71+0.12%
State Street SPDR S&P 500 ETFSPY2.09亿0.03%8172亿 USD0.09%US$778.1-0.06%
Dimensional - US Targeted Value ETFDFAT1.49亿0.50%301.22亿 USD0.33%US$67.42+0.22%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBiShares Core S&P 500 ETFIVVVanguard Morningstar Small-Cap Value ETFVBRState Street SPDR S&P 500 ETFSPYDimensional - US Targeted Value ETFDFATAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
